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Some pharmacological studies showed that diethylcarbamazine (DEC) interferes with the arachidonic
acid metabolism, acting as an anti-inﬂammatory drug. The chronic alcohol consumption activates the
hepatic inﬂammatory response associated to T-cell activation and overproduction of pro-inﬂammatory
cytokines. The present work analyzed the anti-inﬂammatory effect of DEC on hepatic cells of alcoholic
mice. Thirty-two male C57BL/6 mice were equally divided in the following groups: (a) control group
(C), which received only water, (b) DEC-treated group, which received 50 mg/kg for 12 day (DEC50),
(c) the alcoholic group (EtOH), submitted to only alcohol and (d) the alcohol-DEC treated group
(EtOH50), submitted to alcohol plus DEC treatment after the induction of chronic alcoholism for
5 weeks. Biochemical analyses were performed and liver fragments were processed for light
microscopy, transmission electron microscopy, immunohistochemical and western blot. The level of
AST increased signiﬁcantly in alcoholic group whereas a signiﬁcant reduction of serum AST was
detected in the EtOH50 group. Histological and ultrastructural analysis of alcoholic group showed
evident hepatocellular damage, which was strikingly reduced in the alcoholic DEC-treated group.
Immunohistochemistry results revealed highly expression of inﬂammatory markers as MDA, NF-kB,
TNF-a, IL-6, VCAM and ICAM by the hepatic cells of the EtOH group; however no immunoreactivity for
any of these cytokines was detected after DEC treatment. Western blot analyses showed increased
MCP-1 and iNOS expression in EtOH group, which was signiﬁcantly inhibited by DEC treatment.
According to the present results, DEC can be a potential drug for the treatment of chronic inﬂammation
induced by chronic alcoholism.
& 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The harmful use of alcohol is a serious health burden, and it
affects virtually all individuals on an international scale. Health
problems from dangerous alcohol use arise in the form of acute and
chronic conditions, and adverse social consequences are common
when they are associated with alcohol consumption. Every year, the
harmful use of alcohol kills 2.5 million people, including 320 000
young people between 15 and 29 years of age. Alcohol abuse and
alcoholism represents one of the major health, social and economic
issues facing the world (WHO, 2011). Liver is the major site of
ethanol metabolism, and thus the most susceptible organ to alcohol: þ55 81 21012500.
ntos Rocha).
lsevier OA license.induced injury (Kannarkat et al., 2006). Alcoholic liver disease (ALD)
is a collective term for the pathophysiological changes caused by
chronic alcohol consumption, which include oxidative stress gen-
eration, liver steatosis, inﬂammatory response, ﬁbrosis and cirrhosis.
Progression of the disease involves various proinﬂammatory mole-
cules such as interleukins, cytokines, adhesion molecules and
nuclear factor-kB (NF-kB) (Nanji et al., 1999; French, 2002; Achur
et al., 2010; Ballas et al., 2012). The activated NF-kB, if being
translocated into the nucleus, will facilitate transcription of many
downstream genes, including inducible nitric oxide synthase (iNOS)
and cyclooxygenase-2 (COX-2); both are key mediators in recruit-
ment of inﬂammatory cells (Bhaskaran et al., 2010; Arias-Salvatierra
et al., 2011). The iNOS-derived nitric oxide production is activated
downstream of NF-kB, followed by generation of reactive oxygen
species and other free radicals that are detrimental to cells. Cellular
lipids are easily attacked by free radicals, resulting in intracellular
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marked generation of oxidative stress associated with ethanol
metabolism is one of the main liver injuries caused by chronic
alcohol consumption. Oxidative stress causes dysfunctions in several
cellular mechanisms, such as DNA repair and antioxidant systems
(Bardag-Gorce et al., 2000).
Several pharmaco-therapeutic studies have been undertaken to
cure alcoholic hepatitis. The best known are the treatments that block
tumor necrosis factor a (TNF-a) and reduce inﬂammation (pentox-
ifylline, inﬂiximab, etanercept) (Akriviadis et al., 2000; Naveau et al.,
2004; Boetticher et al., 2008). However, these treatments are asso-
ciated with an increase of infections and death, because of this
treatment of alcohol-induced liver disease remains limited to sup-
portive measures (Mullen and Dasrathy, 1998; Barve et al., 2008).
Undoubtedly, the development of effective therapy to prevent or
treat ALD will depend on elucidating the suppression/blockage of any
of the steps culminating into liver injury.
The diethylcarbamazine is the drug most widely used in the
treatment of lymphatic ﬁlariasis since 1947 (Hewitt et al., 1947).
Some studies performed on vertebrates show that this drug has
several direct biochemical effects on different enzyme systems,
including glycolysis, folate metabolism and activity of acetylcho-
linesterase (Subrahmanyam, 1987). DEC also has anti-inﬂamma-
tory properties as a result of its interference with the arachidonic
acid metabolism, which includes lipoxygenases (LOX) and cyclo-
oxygenases (COX) enzymes (Maizels and Denham, 1992; McGarry
et al., 2005). In studies carried out in association with our laboratory,
Queto et al. (2010) demonstrated that DEC has important role in
blocking the pulmonary eosinophilic inﬂammation inmice sensitized
with ovalbumin, effectively preventing the effects of subsequent
airway resistance, Th1/Th2 cytokine production, pulmonary eosino-
phil accumulation and eosinophilopoiesis in vivo and ex vivo. Besides,
DEC directly suppressed IL-5-dependent eosinophilopoiesis in naive
bone marrow.
In this study, for the ﬁrst time, was demonstrated that DEC can
decrease liver injury in experimental alcoholism model, and
revealed a clinical potential of DEC for therapeutic anti-inﬂam-
matory applications.2. Material and methods
2.1. Animals
Thirty-two male C57BL/6 mice at 5 weeks old and weighting
15–16 g were used in all experiments. Mice were examined for
health status and acclimated to the laboratory environment at
23 1C and 12 h light: 12 h dark photoperiod. The animals were
housed in metal cages and fed a standard diet and water ad
libitum. The animal studies Ethics Committee of Oswaldo Cruz
Institute approved all the experiments reported.2.2. Diethylcarbamazine solutions
The solutions were compound of distilled water and DEC
(Farmanguinhos, FIOCRUZ, Brazil) adjusted according to the body
weight of each animal. The groups that were treated received
50 mg/kg of DEC for twelve days through gavage (200 ml) (Saraiva
et al., 2006; Rocha et al., 2012). The control group (C) received just
distilled water by the same administration via. Classical meta-
bolic studies describes the total metabolic rate of a 30 g mouse as
961 kJ per kg body weight, which is approximately seven times
the total metabolic rate of a 70 kg human, 138 kJ per kg (Terpstra,
2001). The lymphatic ﬁlariasis therapeutic dose regimens recom-
mended by WHO is 6 mg/kg for 12 day (WHO, 2011). In thepresent work, we used 50 mg/kg of DEC for 12 day, which is about
seven times the human dose.
2.3. Experimental groups
After a week of acclimation, C57BL/6 mice with 30 day were
separated in four groups (n¼8): (1) Control group (C) that
received just distilled water by the same administration via,
(2) DEC-treated group (D50) that received 50 mg/kg DEC for
twelve days by gavage, (3) alcoholic group (EtOH) that received
ethanol and (4) alcoholic plus 50 mg/kg DEC group (EtOH50).
Ethanol was provided in the drinking water at 10% (v/v) for 2 day,
15% for 5 day, and 20% for 5 weeks (Cook et al., 2004; Ballas et al.,
2012). According to Cook et al. (2004), the mice innate immune
system presents signiﬁcant changes after 3 weeks of 20% ethanol
consumption. The solutions were changed daily and the remain-
ing liquid in the bottles was measured in graduated cylinder for
ﬁnal volume analysis and then discarded. After 5 weeks of
alcoholism induction, mice received alcohol plus treatment for
12 day with DEC solutions orally. The alcoholic group received
alcohol plus water by gavage for 12 day.
2.4. Biochemical determinations
Serum was evaluated for the lipid proﬁle (total cholesterol,
high-density lipoprotein (HDL), low-density lipoprotein (LDL) and
triglyceride) and hepatic damage test (alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phosphatase
(ALP) and bilirrubin). Serum concentrations were measured by
spectrophotometer method in Integra 400– Roche. Data were
compared by ANOVA one way and Dunnet’s or Tukey tests used
GraphPad Prism software, version 5.
2.5. Histopathology
Liver fragments were ﬁxed in 10% formalin for 24 h, processed
and embedded in parafﬁn. Sections 45 mm were cut, mounted
on glass slides. Slices were stained with hematoxylin-eosin and
evaluated with an inverted microscopy (Observer Z1, Zeiss
MicroImaging GmbH) equipped with a camera and 4.7.4 image
analysis program (AxionCam MRm Zeiss) at a magniﬁcation
of 400 .
2.6. Electron transmission microscopy
The fragments of liver were ﬁxed in a solution containing 2.5%
glutaraldehyde and 4% formaldehyde in 0.1 M cacodylated buffer.
After ﬁxation, the samples were washed twice in the same buffer,
and then they were post-ﬁxed in a solution containing 1% osmium
tetroxide, 2 mM calcium chloride and 0.8% potassium ferricyanide
in 0.1 M cacodylate buffer, pH 7.2, dehydrated in acetone, and
embedded in Epon 812 resin (Sigma Company, St Louis, MO).
Polymerization was done at 60 1C for 2 day. Ultrathin sections
were collected on 300-mesh copper grids, counterstained with
uranyl acetate and lead citrate, and examined with a Morgani FEI
transmission electron microscope.
2.7. Immunohistochemical assays
Five sections (5 mm in thickness) of each group were cut and
adhered to slides treated with 3-amino-propyl-trietoxi-silane
(APES [Sigma, USA]). Brieﬂy, sections were deparafﬁnized with
xylene and rehydrated in graded ethanol (100% to 70%). To
increase epitope exposure, the sections were heated for 30 min
in a sodium citrate buffer (0.01 M, pH 6.0). To minimize endo-
genous peroxidase activity, the slides were treated with 0.3% (v/v)
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0.01M PBS (pH 7.2) and then blocked with 1% BSA, 0.2% Tween 20 in
PBS for 1h at room temperature. The sections were then incubated
for 12 h at 4 1C with monoclonal antibody against vascular cell
adhesion molecule-1 (VCAM-1) (eBioscience, San Diego, CA), mono-
clonal antibody against intercellular cell adhesion molecule-1
(ICAM-1) (eBioscience, San Diego, CA) and anti-mouse against
interleukin 6 (IL-6) (eBioscience, San Diego, CA). The optimal
concentration used was 1:100 for these antibodies. For the poly-
clonal antibody against chemokine receptor 2 (CCR2) (ABCAM,
Cambridge, UK), the optimal concentration used was 1:300. Rabbit
anti-NF-kB-p65 (1:50, SC-109; Santa Cruz Biotechnology, CA), or
rabbit anti-TNF-a (1:50, ab66579; Abcam, Cambridge, UK), or rabbit
anti-Malondialdehyde (MDA) antibody (1:50, ab6463; Abcam). The
antigen-antibody reaction was visualized with avidin-biotin perox-
idase (Dako Universal LSABsþKit, Peroxidase) using 3,3-diamino-
benzidine as the chromogen. The slides were counterstained in
hematoxylin. Positive staining resulted in a brown reaction product.
Negative controls were treated as above, but with omission of the
ﬁrst antibody. Five pictures at the same magniﬁcation were quanti-
tatively analyzed using Gimp 2.6 software (GNU Image Manipula-
tion Program, UNIX platforms).2.8. Western blot
Livers were quickly dissected, and then homogenized in a
Wheaton Overhead Stirrer (no. 903475) in an extraction cocktail
(10 mM ethylenediamine tetraacetic acid (EDTA), 2 mM phenyl-
methylsulfonyl ﬂuoride (PMSF), 100 mM sodium ﬂuoride, 10 mM
sodium pyrophosphate, 10 mM sodium orthovanadate (NaVO4),
10mg of aprotinin and 100 mM Tris(hydroxymethyl)amino-
methane, pH 7.4). Homogenates were centrifuged at 3000 g
for 10 min and the supernatant was collected and stored at
70 1C until use for immunoblotting. Protein levels were deter-
mined using the Bradford method using bovine serum albumin as
the standard (Bradford, 1970). The proteins (40 mg) were sepa-
rated on 10% (iNOS and MCP-1) or 14% (CCR2) sodium dodecyl
sulfate-polyacrylamide by gel electrophoresis under reduced
conditions and were electrophoretically transferred onto nitro-
cellulose membrane (Bio Rad, CA, USA, Ref. 162-0115). After
blocking overnight at 4 1C with 5% non-fat milk in TBS-T (Tris-
buffered saline 0.1% plus 0.05% Tween 20, pH 7.4), the membranes
were incubated at room temperature, for 3 h, with rabbit poly-
clonal antibody against iNOS (1:1000 dilution; BD Transduction
Laboratories, USA), MCP-1 (1:500 dilution, Abcam, CA, USA) and
with goat polyclonal antibody against CCR2 (1:3000 dilution,
Abcam, CA, USA ), diluted in buffer solution TBS-T containing 3%
non-fat milk. After washing (six times, 10 min each) in TBS-T, the
membranes were further reacted with horseradish peroxidase-
conjugated anti-rabbit or anti-goat secondary antibody (1:80000
(Ref. A6154), and 1:5000 (Ref. A5420) dilution, respectively,
Sigma, USA), diluted in TBS-T with 1% nonfat milk, for 1 h
30 min, at room temperature. An enhanced chemiluminescence
reagent (Super Signal, Pierce, Ref. 34080) was used to make theTable 1
Values of lipid proﬁle (total cholesterol, LDL, HDL and triglycerides).
Parameter C D50
Total cholesterol (mg/dl) 123.3723.53 109.173
HDL cholesterol (mg/dl) 93.473.64 92.772
LDL cholesterol (mg/dl) 8.8578.132 11.60 71
Triglycerides (mg/dl) 78.83717.62 60.0071
No signiﬁcant difference in the values of lipid proﬁle (total cholesterollabeled protein bands visible and the blots were developed on
X-ray ﬁlm (Fuji Medical, Kodak, Ref. Z358487-50EA). For quanti-
ﬁcation, the density of pixels of each band was determined by the
Image J 1.38 program (available at http://rsbweb.nih.gov/ij/down
load.html; developed by Wayne Rasband, NIH, Bethesda, MD). For
each protein investigated the results were conﬁrmed in three sets
of experiments. Immunoblot for b-actin was done as a control
for the above protein blots. After protein blots visualization
with enhanced chemiluminescence, the protein antibodies were
stripped from the membranes, which were reprobed with mono-
clonal anti-b-actin antibody (1:2000 dilution, Sigma, USA) and
subsequently protein densitometry was done.
2.9. Statistical analyses
For statistical analyses we used GraphPad Prism software, version
5. Data were expressed with mean7standard deviation. Differences
between control and treated groups were analyzed used analysis of
variance (ANOVA) and Dunnett or Tukey’s or T tests as post hoc tests.
Probability values less than 0.05 were considered signiﬁcant.3. Results
3.1. Ethanol consumption
Among the data analyzed, no signiﬁcant difference in ethanol
consumption between the alcoholic group EtOH (179.477.522) and
EtOH50 (181.276.631) was observed throughout the experiment.
Besides, no difference was observed in the body mass between EtOH
group (20.2672.723) and EtOH50 group (20.5972.407).
3.2. Serum biochemistry
No signiﬁcant difference in lipid proﬁle (total cholesterol, LDL,
HDL and triglycerides) was observed between groups exposed to
ethanol (EtOH) and groups exposed to ethanol plus DEC-treat-
ment (EtOH50), when compared to the control group (Table 1).
Regarding to the liver enzymes, the serum ALT, ALP and bilirrubin
evaluations showed no signiﬁcant differences among the groups.
However, in relation to the AST analyses, there was no signiﬁcant
difference in serum AST between DEC-treated (D50) (116.8731.8)
and control group (C) (80.11731.35) but, the level of AST increased
signiﬁcantly in the alcoholic group (EtOH) (169.8758.92) when
compared with the control group (C) (80.11731.35) (Table 2). We
observed a signiﬁcant reduction of serum AST in the alcoholic
DEC-treated group (EtOH50) (102.6713.34) when compared to the
alcoholic group that received no treatment (EtOH) (Table 2). In
addition, the EtOH50 group reached AST serum levels similar to the
control group (C).
3.3. Histopathology of the liver
Histological analysis of liver fragments of the control group
(C) showed well-preserved tissue, composed of radially arrangedEtOH EtOH50
6.58 90.8718.61 96.3720.30
7.43 82.5710.75 84.5715.01
3.25 8.7576.654 10.6576.362
5.85 79.00721.15 69.00720.47
, LDL, HDL and triglycerides) were observed between groups.
Table 2
Values of serum enzyme aspartate aminotransferase (AST U/L), alanine aminotransferase (ALT U/L), alkaline phosphatese (AP mg/dl) and
bilirubin (mg/dl).
Parameter C D50 EtOH EtOH50
AST (U/L) 80.1731.35 110.7729.42 169.8718.92a 102.6713.34b
ALT (U/L) 26.107 9.78 39.28712.52 22.63 75.93 22.3073.75
ALP (mg/dl) 104.275.78 109.777.23 142.9759.39 113.4710.27
Bilirubin (mg/dl) 0.128370.02 0.138370.05 0.188670.02 0.114370.04
a Signiﬁcant increase in the values of AST in EtOH group compared to the control group (C).
b Signiﬁcant decrease in the values of AST in EtOH50 group when compared with the group EtOH. Po0.05 (aPo0.05, bPo0.03).
AST—aspartate aminotransferase, ALT—alanine aminotransferase, ALP—alkaline phosphatese. The serum ALT, alkaline phosphatase and
bilirubin avaliations showed no signiﬁcant differences among the groups.
V
V
Li
*
*
Li
V
20µm
Fig. 1. Micrograph of hepatocytes. (A) Control group (C) showing typical morphology, (B) Group treated with 50 mg/kg DEC (D50), (C) Alcoholic group (EtOH).
(D) Alcoholic plus 50 mg/kg DEC group (EtOH50). Blood vessel (V), hydropic degeneration (arrow), lipid droplets (Li), necrosis (asterisk), inﬂammatory inﬁltrates (star),
macrophages (arrowhead), HE staining, Bar¼20 mm.
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12 day DEC treatment (D50), no alterations were observed in the
liver parenchyma, including the glycogen stores (Fig. 1B).
In hepatic histological sections of the group that received
treatment with ethanol (EtOH), the most evident histological
alteration was the presence of macro-and microvesicular lipid
droplets in the cytoplasm of hepatocytes, which characterizes the
steatosis process (Fig. 1C). Furthermore, multiple foci of inﬂam-
matory inﬁltrates we observed mainly composed by macrophages
next to the endothelium vessel. Focal necrosis areas were also
presented in the hepatic parenchyma (Fig. 1C).
The group that received ethanol and was treated for 12 day
with 50 mg/kg of DEC (EtOH50) presented a reduced number of
lipid droplets (Fig. 1D). An important decrease in inﬂammatory
inﬁltrates was observed. In addition, no necrosis areas were
observed (Fig. 1D).
3.4. Ultrastructural changes
The ultrastructural analysis of hepatocytes of the control group
showed typical morphological pattern as rough endoplasmicreticulum, mitochondria, glycogen granules, and nucleus present-
ing evident nucleoli (Fig. 2A). The hepatocytes of the DEC-treated
group for 12 day with 50 mg/kg (D50) presented typical glycogen
stores, however, showed slight proliferation of rough endoplasmic
reticulum membranes (Fig. 2B).
Ultrastructural analysis of the alcoholic group (EtOH) revealed
chronic cell injury characterized by the presence of several lipids
droplets as well as an amorphous accumulation of glycogen in the
cytoplasm (Fig. 2C). Several necrotic cells presented vacuolated
organelles and disarrangement of cytoplasm (Fig. 2C).
The hepatocytes of alcoholic group that received DEC treat-
ment (EtOH50) presented typical morphology exhibiting well-
preserved organelles similar to the control group (Fig. 2D).3.5. Immunohistochemical analysis
Administration of alcohol produced severe liver damage as
indicated by markedly increased malondialdehyde (MDA). Immu-
nohistochemical staining showed that MDA was highly accumu-
lated in the hepatic tissue principally around lipid droplets in
N
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M
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P
M
RER
G
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M
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Fig. 2. Ultrathin sections of hepatocytes. (A) Control group (C). (B) 50 mg/kg DEC-treated group (D50). (C) Hepatocytes of alcoholic group (EtOH). (D) Alcoholic plus 50 mg/
kg DEC group (EtOH50). Observe mitochondrial damage and disarrangement cytoplasmatic in hepatocytes of alcoholic group (arrows). Mitochondria (M), glycogen (G),
nucleus (N), rough endoplasmic reticulum (RER), lipid droplets (Li), lysosomes (L). Magniﬁcation 7100 .
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EtOH50 group (Fig. 3B).
NF-kB is a transcription factor which regulates genes involving
in inﬂammation. The activation of NF-kB has been shown in
alcohol-induced liver injury. We performed immunohistochem-
ical staining with an antibody against the activated p65 subunit of
NF-kB to evaluate the distribution of NF-kB in the hepatic tissue.
High level of NF-kB expression was seen in hepatocytes and
macrophages exposed to alcohol (Fig. 3C), which was not
observed in the hepatocytes of the EtOH50 group (Fig. 3D).
TNF-alpha (TNF-a) is the key mediator in many experimental
liver injury models, including alcohol-induced hepatitis. To further
understand how DEC may attenuate hepatic inﬂammatory responses
after alcohol exposure, we examined TNF-a expression in EtOH and
EtOH50 groups of this study. The expression of TNF-a was highly
induced by ethanol exposure (Fig. 3E), mainly in necrotic areas and
macrophages. TNF-a immunopositivity decreased signiﬁcantly in the
livers of alcohol-induced mice treated with the DEC (50mg/kg)
(Fig. 4F).
The immunohistochemical labeling of IL-6 in the alcoholic
group (EtOH) was located in the cytoplasm of Kupffer cells, as
well as in some endothelial cells and hepatocytes membrane
(Fig. 3G). However, the group subjected to ethanol plus 50 mg/kg
DEC had no speciﬁc staining for this cytokine (Fig. 3H).
By analyzing the expression of VCAM-1, which is a key
determinant for recruitment of leukocytes to the site of inﬂam-
mation, there was a immunostaining in endothelial cells of
hepatic sinusoids and others blood vessels in the group submitted
alcoholism (EtOH) (Fig. 3I). Conversely, a signiﬁcant reduction of
this labeling was observed in animals subjected to ethanol plus
50 mg/kg DEC treatment (EtOH50) (Fig. 3J).
Regarding the immunohistochemical staining of ICAM-1 in hepa-
tic cells of the EtOH group, there was a large amount of immunor-
eactive Kupffer cells and endothelial cells (Fig. 3K). The expressionof these molecules has been attributed the work of facilitating the
transmigration of leukocytes across the vascular endothelium in
inﬂammatory processes. The alcoholic group plus 50mg/kg DEC
treatment (EtOH50) did not show any labeling for ICAM-1 (Fig. 3L).
The chemokine receptor ligand 2 (CCR2) presented immunos-
taining in the cytoplasm of Kupffer cells of the EtOH group (Fig. 3M),
which is characteristic of acute or chronic inﬂammatory response.
The group EtOH50 showed a reduced labeling for CCR2, however,
the quantitative analyses showed no signiﬁcance (Fig. 3N).
3.6. Expression of hepatic iNOS, MCP-1 and CCR2 proteins
In this study, we also investigated the effect of DEC (50 mg/kg)
on the expression of iNOS, MCP-1 and CCR2 proteins of hepatic
cells of alcoholic mice.
The alcoholic group (EtOH) presented higher levels of iNOS
(120 kDa) expression than control samples. However, DEC treat-
ment of the alcoholic mice (EtOH50) group resulted in decreased
of iNOS expression (Fig. 4A and B).
Similarly, EtOH group presents a signiﬁcant MCP-1 (18 kDa)
increase, which is a cytokine involved in the leukocyte recruit-
ment. On the other hand, the treatment with DEC (50 mg/kg) of
the alcoholic mice reduced signiﬁcantly when compared to the
EtOH group (Fig. 4C and D).
Analyzing the CCR2 (42 kDa) protein expression, no difference
was detected among groups, conﬁrming previous results obtained
by immunohistochemistry (Fig. 4E and F).4. Discussion
Animal models of ethanol abuse have also been reported to
show increased susceptibility to inﬂammation, and both human
beings and animals chronically exposed to excess ethanol have a
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These alterations include increases in T-cell activation in both
human alcoholics (Cook et al., 1991; Cook et al., 1994; Cook et al.,
1995) and mice consuming ethanol chronically (Song et al., 2002),IL-6  EtOH EtOH50 
EtOH NFkB EtOH50 
EtOH TNF-a EtOH50 
EtOH MDA EtOH50 
Fig. 3. Immunohystochemical analyses for MDA, NFkB, TNF-a, IL-6, VCAM-1, ICAM-1, a
(J), (L) and (N) Alcoholic plus 50 mg/kg DEC-treated group (EtOH50). Observe intense lab
(M) present in the hepatocytes of the EtOH group. Reduced staining after 50 mg/kg DEC
(L) and CCR-2 (N). The quantiﬁcation of cytokines staining (mean7S.D., n¼5). *Po0.0which through T cell receptor for antigen (TCR) induce a rapid
inﬂammatory response (Song et al., 2001; Song et al., 2002).
Two weeks of ethanol administration to a mouse is equivalent
to a little over 1 year for a human, so it seems desirable to exploreIL-6  
EtO
H
EtO
H5
0
0
100000
200000
300000
400000
IL
-6
 q
ua
nt
ifi
ca
tio
n 
(P
ixe
ls)
EtO
H
EtO
H5
0
0.0
200000.0
400000.0
600000.0
800000.0
1000000.0
N
Fk
B 
qu
an
tif
ic
at
io
n 
(P
ixe
ls)NFkB 
Et
OH
EtO
H5
0
0
100000
200000
300000
400000
TN
F-
al
ph
a 
qu
an
tif
ic
at
io
n 
(P
ixe
ls)TNF-a
Et
OH
EtO
H5
0
0
100000
200000
300000
400000
500000
M
D
A
 q
ua
nt
ifi
ca
tio
n 
(P
ixe
ls)
MDA 
*
*
*
**
nd CCR2. (A), (C), (E), (G), (I), (K) and (M) Alcoholic group (EtOH). (B), (D), (F), (H),
eling for MDA (A), NFkB (C), TNF-a (E), IL-6 (G), VCAM-1 (I), ICAM-1 (K) and CCR-2
treatment (EtOH50) for MDA (B), NFkB (D), TNF-a (F), IL-6 (H), VCAM-1 (J), ICAM-1
5, **Po0.01 as compared with the control group. Bars¼20 mm.
Et
OH
Et
OH
50
0.0
500000.0
1000000.0
1500000.0
*
V
C
A
M
 q
ua
tif
ic
at
io
n 
(P
ix
el
s)
Et
OH
Et
OH
50
0
50000
100000
150000
200000
250000
**IC
A
M
 q
ua
nt
ifi
ca
tio
n 
(P
ix
el
s)
EtOH50 VCAM 
ICAM-1 ICAM-1 EtOH50EtOH
EtOH VCAM 
Et
OH
Et
OH
50
0
100000
200000
300000
400000
C
C
R
2 
qu
an
tif
ic
at
io
n 
(P
ix
el
s)
EtOH CCR2 EtOH50 CCR2 
Fig. 3. (continued)
S.W. Santos Rocha et al. / European Journal of Pharmacology 689 (2012) 194–203200protocols that are equivalent to several years of heavy drinking
in the human (Cook, 1998). In the present study, we have used
period of 5 weeks at ethanol consumption, which is at near the
maximum tolerated by mice on a chronic basis.
The chronic consume alcohol is associated with the overproduc-
tion of proinﬂammatory cytokines such as interleukin-1b (IL-1b),
IL-8 and IL-6 (McClain and Cohen, 1989; Hill et al., 1993). These
cytokines play a vital pathological role in the development of
alcoholic liver disease (ALD), as demonstrated commonly in animal
models, and mediates monocyte/Kupffer cell activation, vascular
permeability elevation, necrosis and/or apoptosis of hepatocytes,
overexpression of adhesion molecules on endothelial cells, and the
activation and chemoattraction of neutrophils and mononuclear cells
(Mathurin et al., 1998; Thurman, 1998). Besides, individuals that
chronically consume alcohol present an increase of lipid deposits in
hepatocytes and inﬂammatory responses (Kozawa et al., 2007).
According to Rocha et al. (2012) malnourished animals treated with
DEC 25 and 50mg/kg, prevented the lipid accumulation
and promoted a reduction of the damage caused by malnutrition.
Gonzalez et al. (1994) showed that rats with inﬂammation induced
by CCl4 had a reduction of liver damage after DEC treatment at 25
and 50 mg/kg, such as, well-preserved organelles and membranesystem of hepatocytes, showing that DEC had a protective effect.
In the present work, the alcoholic-group (EtOH) presented an evident
lipid accumulation and a cytoplasmatic disarrangement was
observed by histology and ultrastructural assays. However, a reduc-
tion of lipid droplets and inﬂammatory inﬁltrates was observed in
DEC-treated group (EtOH50). Moreover, DEC-treated group showed
an evident reduction of morphological damage, conﬁrming previous
studies.
Liver injury after ethanol treatment is a common phenom-
enon, and the obvious indicator of liver injury is the leakage of
cellular enzymes into plasma (Baldi et al., 1993). The increase in
serum enzymes levels associated with ALT and AST has been
observed in ethanol-treated rats, which show enhanced perme-
ability, injury and necrosis of hepatocytes (Goldberg and Watts,
1965). However, Kerai et al. (1999) studying a chronic model of
alcoholism showed raised levels of serum AST in contrast to
standard levels of ALT. Corroborating to these data, the results of
the present study showed an increase of serum AST in EtOH
group, which is characteristic of abusive consumption of ethanol.
However, after DEC treatment (EtOH50), a signiﬁcant reduction in
serum levels of AST was detected, suggesting that DEC decreased
the hepatic parenchyma injury.
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Fig. 4. Western blot analysis of liver expression. ((A) and (B)) The expression of iNOS presented signiﬁcant difference between EtOH and control group (*Po0.05). Data
were analyzed by one-way ANOVA followed by the Dunnet and Tukey tests. Treatment with 50 mg/kg DEC (EtOH50) reduced signiﬁcantly the iNOS expression in alcoholic
induced mice (#Po0.05). ((C) and (D)) MCP-1 content measured by pixels quantiﬁcation of WB bands showed signiﬁcant difference between EtOH, EtOH50 and control
groups. #Po0.05, EtOH group when compared with control group. *Po0.05, EtOH50 group when compared with EtOH group. Data were analyzed by one-way ANOVA
followed by the Dunnet and Tukey tests. The columns represent the mean7S.D. of the protein investigated; the results were conﬁrmed in three sets of experiments
(n¼5 animals). ((E) and (F)) Panels E and F show CCR2 blots and WB quantiﬁcation represented by bars; no signiﬁcant difference was seen regarding the CCR2 expression
both in EtOH50 and EtOH groups when compared to control. There was no signiﬁcant difference between EtOH50 and EtOH groups when compared to control group. Data
were analyzed by one-way ANOVA followed by the Dunnet or Tukey or T tests. The columns represent the mean7S.D. of the protein blot investigated; the results were
conﬁrmed in three sets of experiments (n¼5 animals).
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cal defense mechanisms, evidenced as granulocitopoiese, chemotaxis,
phagocytosis and cytotoxicity (Dani, 2001; Crews et al., 2006).
Alcohol is known to alter cytokine levels in a variety of tissues,
including plasma, lung, liver, and brain (Panesar et al., 1999).
EtOH group presented marked immunoexpression of inﬂam-
matory mediators MDA, NF-kB, TNF-a, IL-6, MCP-1, iNOS, ICAM-1,
VCAM-1 and. According to our results, treatment with DEC, in
turn, acted by decreasing the expression of proinﬂammatory
cytokines in endothelial cells of sinusoids and blood vessels,
hepatocytes and Kupffer cells of intoxicated (EtOH50) mice.
It is well known that oxidation and inﬂammation are closely
interrelated in biological systems, and this interaction facilitates
the progression of several diseases (Furnkranz et al., 2005; Ley
and Deem, 2005). Malondialdehyde is a naturally occurring
product of lipid peroxidation and prostaglandin biosynthesis that
is mutagenic and carcinogenic (Marnett, 1999). Lipid peroxidationhas been implicated in the pathogenesis of hepatic injury by
ethanol, which leads to membrane dysfunction (Bandyopadhyay
et al., 1999). In the present study, increased MDA, a product of
lipid peroxidation, observed in the liver of ethanol-administered
mice indicated excessive formation of free radicals resulting in
hepatic damage. In contrast, DEC treatment reduced the MDA
levels suggesting a possible antioxidant action.
Nuclear factor B (NF-kB) is a transcription factor associated to
the spreading of the innate immune cascade (Ghosh and Hayden,
2008). According to Zou and Crews, 2010 ethanol could initially
activate NF-kB through reactive oxygen species and/or release of
proinﬂammatory cytokines, such as TNF-a and MCP-1. TNF-a is a
target gene of the NF-kB signaling pathway and may act as an
autocrine/paracrine factor stimulating the cytocine production
and activation of NF-kB signaling pathway.
It has been indicated that tumor necrosis factor-alpha (TNF-a)
and interleukin-6 (IL-6) are involved in the progression of
S.W. Santos Rocha et al. / European Journal of Pharmacology 689 (2012) 194–203202ethanol-induced hepatotoxicity (Yang et al., 2003; McClain et al.,
2004; Naveau et al., 2005). The increased release of these
inﬂammatory factors, which is partially due to the stimulation
of oxidative stress, could consequently lead to cytokine imbal-
ance, immune dysfunction and even liver cell apoptosis. Our
present study showed that DEC treatment markedly suppressed
the release of IL-6 and TNF-a.
Monocyte chemotactic peptide-1 (MCP-1) is a member of the
beta (C–C) chemokine family (Loetscher et al., 1994). MCP-1 is
secreted by a variety of cell types in response to endotoxin
(lipopolysaccharide, LPS) and cytokines such as TNF-a and inter-
leukin 1 (IL-1). MCP-1 activates and chemotactically attracts
monocytes/macrophages (Leonard and Yoshimura, 1990; Kunkel
et al., 1991; Loetscher et al., 1994). Besides, MCP-1 gene regula-
tion is closely associated to the oxidative stress sensitive NF-kB
(Czaja et al., 1994; Sato et al., 1996). Various types of liver cells such
as stellate cells (liver fat storing cells) and rat liver endothelial cells
have been shown to produce MCP-1 (Ebnet et al., 1997; Marra et al.,
1993). We demonstrated that levels of MCP-1 were signiﬁcant
elevated in the EtOH group when compared with control and
EtOH50 groups. Treatment with DEC (EtOH50) reduced striking
the MCP-1 expression, possibly by inhibiting the NF-kB activation.
Chemokines and chemokine receptors play a central role in
regulating cell migration to the site of inﬂammation (Bachmann
et al., 2006). The C2 chemokine receptor (CCR2) mainly expressed
on surface of monocytes and Kupffer cells, is a functional receptor
for MCP-1, MCP-2 and MCP-3 and acts recruiting these cells to the
site inﬂammation (Feterowski et al., 2004; Weisberg et al., 2006).
The recruitment and migration of Kupffer cells and stellate cells
are critical events for the development of liver inﬂammation and
ﬁbrosis (Bataller and Brenner, 2005; Friedman, 2008). Our results
showed by immunohistochemistry and immunoblot that the
alcoholic-group had no difference signiﬁcant in CCR2 activity
and expression when compared to control animals. According to
Cullen et al. (2005), the ethanol can altered MCP-1 expression in
IL-1-activated human endothelial cells without altering the CCR2
receptor binding activity in monocytes. This data conﬁrm our
results, since despite of MCP-1 expression is activated, the CCR2
did not get changes due to effects of chronic alcoholism.
According to Baraona et al. (2002), chronic EtOH exposure
presented an increase of NO by 52% and iNOS activity in the liver
by 5-fold (Baraona et al., 2002). iNOS activity and expression were
associated with the severity of liver damage, especially the
necroinﬂammation, suggesting that iNOS contributes to alcohol-
induced liver injury (Yuan et al., 2006). Activated NF-kB, a
transcription factor, may bind to the speciﬁc DNA sequence of
iNOS to promote its expression (Spink et al., 1995). We showed
that the alcoholic group (EtOH) presented higher levels of iNOS
(120 kDa) expression. However, DEC treatment of the alcoholic
mice (EtOH50) group resulted in decreased of iNOS expression.
Our results are in agreement to those above described. The
increased iNOS expression could activate the production reactive
oxygen species and inﬂammatory cytokines, which subsequently
play a key role in hepatic inﬂammation. iNOS has been shown to
increase the expression of adhesion molecules and orchestrate
the transcriptional regulation of cytokines through its effects on
NF-kB (Cuzzocrea et al., 2002).
Several conditions can activate endothelial cells inducing the
expression of adhesion molecules (AM) on the surface of these
cells (Sacanella and Estruch, 2003). The vascular cell adhesion
molecule-1 (VCAM-1) and intercellular cell adhesion molecule
(ICAM-1) are minimally expressed in no activated endothelium,
but elevated in inﬂammatory processes (Springer, 1990;
Bevilacqua, 1993). Alcoholic beverages and cirrhosis are asso-
ciated with high regulation of ICAM-1 and VCAM-1 in vessels and
sinusoidal endothelium (Adams et al., 1994; Fisher et al., 1996).The elevated immune expression of the ICAM-1 and VCAM-1 in
the EtOH group conﬁrmed that the abuse of alcohol intake
increases the levels of these cytokines in endothelials cells and
macrophages. As for the other inﬂammatory markers studied, DEC
inhibited the expression of these adhesion molecules in EtOH50
mice group.
In summary, the present study found that chronic consump-
tion of ethanol increased NF-kB and target several proinﬂamma-
tory cytokines, chemokines and oxidases. The administration of
DEC inhibited the hepatic injury and decreased inﬂammatory
markers, suggesting a potential therapeutical use in chronic
inﬂammation induced by alcoholism. Further investigations to
conﬁrm the anti-inﬂammatory and hepatoprotector role of DEC in
the pathogenesis of alcoholism are underway in our laboratory.Acknowledgements
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